[{"id":"58d26922-dd62-4243-8588-89fbcbf5d940","acronym":"","url":"https://clinicaltrials.gov/study/NCT02152995","created_at":"2021-03-24T14:59:26.184Z","updated_at":"2025-02-25T12:26:08.615Z","phase":"Phase 2","brief_title":"Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer","source_id_and_acronym":"NCT02152995","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • KRAS • BRAF • NRAS • HRAS • EGF","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • BRAF V600 • BRAF wild-type • RAS wild-type • HRAS mutation • KRAS G12 • NRAS Q61 • KRAS G13 • NRAS G12 • NRAS G13 • KRAS Q61","tags":["HER-2 • KRAS • BRAF • NRAS • HRAS • EGF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • BRAF V600 • BRAF wild-type • RAS wild-type • HRAS mutation • KRAS G12 • NRAS Q61 • KRAS G13 • NRAS G12 • NRAS G13 • KRAS Q61"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • omipalisib (GSK2126458)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 34","initiation":"Initiation: 08/14/2014","start_date":" 08/14/2014","primary_txt":" Primary completion: 08/25/2021","primary_completion_date":" 08/25/2021","study_txt":" Completion: 01/25/2026","study_completion_date":" 01/25/2026","last_update_posted":"2025-02-24"},{"id":"1ee7d622-cdd0-4c14-a5ad-ff67b7a251a6","acronym":"NCI-2021-11793","url":"https://clinicaltrials.gov/study/NCT05111561","created_at":"2021-11-08T14:53:11.471Z","updated_at":"2025-02-25T13:40:41.596Z","phase":"Phase 1","brief_title":"Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer","source_id_and_acronym":"NCT05111561 - NCI-2021-11793","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • KRAS • BRAF • ER • PGR • NRAS • HRAS • NF1","pipe":" | ","alterations":" BRAF mutation • HER-2 amplification • HRAS mutation • BRAF fusion","tags":["HER-2 • KRAS • BRAF • ER • PGR • NRAS • HRAS • NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • HER-2 amplification • HRAS mutation • BRAF fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mektovi (binimetinib) • ZEN-3694"],"overall_status":"Suspended","enrollment":" Enrollment 42","initiation":"Initiation: 08/02/2022","start_date":" 08/02/2022","primary_txt":" Primary completion: 03/14/2025","primary_completion_date":" 03/14/2025","study_txt":" Completion: 03/14/2025","study_completion_date":" 03/14/2025","last_update_posted":"2025-02-21"},{"id":"9746c38a-e183-480a-bcc4-ea83361a9977","acronym":"","url":"https://clinicaltrials.gov/study/NCT05554328","created_at":"2022-09-26T14:56:09.383Z","updated_at":"2025-02-25T13:49:33.072Z","phase":"Phase 2","brief_title":"Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial","source_id_and_acronym":"NCT05554328","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KRAS • BRAF • NRAS • HRAS • MAP2K1 • NF1 • MAP2K2","pipe":" | ","alterations":" KRAS mutation • BRAF mutation • NRAS mutation • RAS mutation • HRAS mutation","tags":["KRAS • BRAF • NRAS • HRAS • MAP2K1 • NF1 • MAP2K2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF mutation • NRAS mutation • RAS mutation • HRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Koselugo (selumetinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 165","initiation":"Initiation: 04/25/2023","start_date":" 04/25/2023","primary_txt":" Primary completion: 10/01/2028","primary_completion_date":" 10/01/2028","study_txt":" Completion: 10/01/2028","study_completion_date":" 10/01/2028","last_update_posted":"2025-02-20"},{"id":"fb4d840f-ccf1-4e5e-ac00-2c10191c007e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05554367","created_at":"2022-09-26T14:56:10.119Z","updated_at":"2025-02-25T13:54:43.263Z","phase":"Phase 2","brief_title":"Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial","source_id_and_acronym":"NCT05554367","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KRAS • BRAF • NRAS • HRAS • RAS","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • KRAS G12C • HRAS mutation • KRAS G12","tags":["KRAS • BRAF • NRAS • HRAS • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • KRAS G12C • HRAS mutation • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Mektovi (binimetinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 199","initiation":"Initiation: 12/13/2023","start_date":" 12/13/2023","primary_txt":" Primary completion: 08/26/2026","primary_completion_date":" 08/26/2026","study_txt":" Completion: 08/26/2026","study_completion_date":" 08/26/2026","last_update_posted":"2025-02-20"},{"id":"bb866355-1e34-4d35-9bb4-a41598c5e17e","acronym":"IMM1104-101","url":"https://clinicaltrials.gov/study/NCT05585320","created_at":"2022-10-18T14:57:21.622Z","updated_at":"2025-02-25T14:09:12.843Z","phase":"Phase 1/2","brief_title":"A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT05585320 - IMM1104-101","lead_sponsor":"Immuneering Corporation","biomarkers":" KRAS • HRAS • APC","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • KRAS wild-type • RAS mutation • HRAS mutation","tags":["KRAS • HRAS • APC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • KRAS wild-type • RAS mutation • HRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium • atebimetinib (IMM-1-104)"],"overall_status":"Recruiting","enrollment":" Enrollment 210","initiation":"Initiation: 10/31/2022","start_date":" 10/31/2022","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2025-02-19"},{"id":"12b710b2-1109-43fb-8b55-f68f0578591b","acronym":"FIT-001","url":"https://clinicaltrials.gov/study/NCT06026410","created_at":"2023-09-07T16:09:33.674Z","updated_at":"2025-02-25T14:18:15.893Z","phase":"Phase 1","brief_title":"KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors","source_id_and_acronym":"NCT06026410 - FIT-001","lead_sponsor":"Kura Oncology, Inc.","biomarkers":" KRAS • NRAS • HRAS","pipe":" | ","alterations":" KRAS mutation • HRAS mutation","tags":["KRAS • NRAS • HRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • HRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cabometyx (cabozantinib tablet) • Krazati (adagrasib) • darlifarnib (KO-2806)"],"overall_status":"Recruiting","enrollment":" Enrollment 270","initiation":"Initiation: 10/18/2023","start_date":" 10/18/2023","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 04/01/2027","study_completion_date":" 04/01/2027","last_update_posted":"2025-02-12"},{"id":"79a21cb0-b80b-4f09-9b9e-bdba02cd1248","acronym":"IMPACT","url":"https://clinicaltrials.gov/study/NCT01505400","created_at":"2021-01-18T06:19:22.670Z","updated_at":"2025-02-25T16:58:29.958Z","phase":"","brief_title":"Integrated Molecular Profiling in Advanced Cancers Trial","source_id_and_acronym":"NCT01505400 - IMPACT","lead_sponsor":"University Health Network, Toronto","biomarkers":" EGFR • HER-2 • PIK3CA • FGFR2 • STK11 • HRAS • PDGFRA • JAK2 • AKT1 • FGFR4 • CTNNB1","pipe":"","alterations":" ","tags":["EGFR • HER-2 • PIK3CA • FGFR2 • STK11 • HRAS • PDGFRA • JAK2 • AKT1 • FGFR4 • CTNNB1"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 3026","initiation":"Initiation: 02/01/2012","start_date":" 02/01/2012","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2025-02-03"},{"id":"a32ecad7-5454-46b4-8444-9e5355b8f01d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03162627","created_at":"2021-01-18T15:35:40.609Z","updated_at":"2025-02-25T14:58:06.370Z","phase":"Phase 1","brief_title":"Selumetinib and Olaparib in Solid Tumors","source_id_and_acronym":"NCT03162627","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" KRAS • BRAF • HRAS • NF1 • MUC16","pipe":"","alterations":" ","tags":["KRAS • BRAF • HRAS • NF1 • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Koselugo (selumetinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 08/04/2017","start_date":" 08/04/2017","primary_txt":" Primary completion: 08/30/2026","primary_completion_date":" 08/30/2026","study_txt":" Completion: 08/30/2026","study_completion_date":" 08/30/2026","last_update_posted":"2024-10-16"},{"id":"1aa44e24-9704-4fe0-a608-34236855cfe0","acronym":"19-C-0017","url":"https://clinicaltrials.gov/study/NCT03745326","created_at":"2021-01-18T18:20:39.102Z","updated_at":"2024-07-02T16:34:38.005Z","phase":"Phase 1/2","brief_title":"Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients","source_id_and_acronym":"NCT03745326 - 19-C-0017","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • PD-L1 • KRAS • ALK • NRAS • HRAS","pipe":" | ","alterations":" PD-L1 expression • KRAS mutation • NRAS mutation • KRAS G12D • EGFR expression • HRAS mutation • KRAS G12 • NRAS G12D • NRAS G12 • HLA-A*11","tags":["EGFR • PD-L1 • KRAS • ALK • NRAS • HRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • KRAS mutation • NRAS mutation • KRAS G12D • EGFR expression • HRAS mutation • KRAS G12 • NRAS G12D • NRAS G12 • HLA-A*11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • anti-KRAS G12D mTCR PBL • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 05/16/2019","start_date":" 05/16/2019","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2024-06-05"},{"id":"92f8d52f-8230-4bcf-832a-25726a2e7d8a","acronym":"","url":"https://clinicaltrials.gov/study/NCT03190941","created_at":"2021-01-18T15:44:01.911Z","updated_at":"2024-07-02T16:34:38.067Z","phase":"Phase 1/2","brief_title":"Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients","source_id_and_acronym":"NCT03190941","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KRAS • ALK • NRAS • HRAS","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • KRAS G12V • HRAS mutation • KRAS G12 • NRAS G12 • HLA-A*11 • NRAS G12V","tags":["KRAS • ALK • NRAS • HRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • KRAS G12V • HRAS mutation • KRAS G12 • NRAS G12 • HLA-A*11 • NRAS G12V"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 09/21/2017","start_date":" 09/21/2017","primary_txt":" Primary completion: 06/29/2027","primary_completion_date":" 06/29/2027","study_txt":" Completion: 06/29/2028","study_completion_date":" 06/29/2028","last_update_posted":"2024-06-05"},{"id":"77cb581e-c173-4f2c-a06e-c96db7736264","acronym":"RAS-HEMATO","url":"https://clinicaltrials.gov/study/NCT04286360","created_at":"2021-01-18T20:48:27.393Z","updated_at":"2024-07-02T16:34:59.177Z","phase":"","brief_title":"Hematological Anomalies in Children With Rasopathy","source_id_and_acronym":"NCT04286360 - RAS-HEMATO","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","biomarkers":" KRAS • BRAF • NRAS • HRAS • MAP2K1 • NF1 • PTPN11 • MAP2K2 • RAF1 • RIT1 • LZTR1","pipe":" | ","alterations":" BRAF mutation • CBL mutation • MAP2K1 mutation","tags":["KRAS • BRAF • NRAS • HRAS • MAP2K1 • NF1 • PTPN11 • MAP2K2 • RAF1 • RIT1 • LZTR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • CBL mutation • MAP2K1 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 11/11/2020","start_date":" 11/11/2020","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 11/01/2029","study_completion_date":" 11/01/2029","last_update_posted":"2024-06-04"},{"id":"6c758fa1-b102-4d99-aa19-27558b9979c8","acronym":"MegaMOST","url":"https://clinicaltrials.gov/study/NCT04116541","created_at":"2021-01-18T20:07:18.206Z","updated_at":"2024-07-02T16:35:12.639Z","phase":"Phase 2","brief_title":"A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.","source_id_and_acronym":"NCT04116541 - MegaMOST","lead_sponsor":"Centre Leon Berard","biomarkers":" KRAS • BRAF • ALK • FLT3 • NRAS • ROS1 • NTRK2 • HRAS • CDKN2A • NF1 • AXL • CCND1 • CDK4 • PTPN11 • SMAD4 • RAF1 • FLT1 • CDK6 • CCND3 • TYRO3 • NTRK","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • BRAF mutation • NRAS mutation • BRAF V600 • FGFR1 amplification • CDKN2A deletion • HRAS mutation • PTPN11 mutation • CCND1 amplification • KRAS amplification • BRAF amplification","tags":["KRAS • BRAF • ALK • FLT3 • NRAS • ROS1 • NTRK2 • HRAS • CDKN2A • NF1 • AXL • CCND1 • CDK4 • PTPN11 • SMAD4 • RAF1 • FLT1 • CDK6 • CCND3 • TYRO3 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • BRAF mutation • NRAS mutation • BRAF V600 • FGFR1 amplification • CDKN2A deletion • HRAS mutation • PTPN11 mutation • CCND1 amplification • KRAS amplification • BRAF amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Tafinlar (dabrafenib) • Alecensa (alectinib) • Cabometyx (cabozantinib tablet) • Stivarga (regorafenib) • Kisqali (ribociclib) • Ayvakit (avapritinib) • siremadlin (HDM201)"],"overall_status":"Recruiting","enrollment":" Enrollment 455","initiation":"Initiation: 01/28/2020","start_date":" 01/28/2020","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2024-03-27"},{"id":"0ff46655-3196-4e55-a296-9ffdaa5cc8b1","acronym":"UTAH","url":"https://clinicaltrials.gov/study/NCT04145297","created_at":"2021-01-18T20:14:00.569Z","updated_at":"2024-07-02T16:35:13.869Z","phase":"Phase 1","brief_title":"Ulixertinib (BVD-523) and Hydroxychloroquine in Patients w Advanced MAPK-Mutated Gastrointestinal Adenocarcinomas","source_id_and_acronym":"NCT04145297 - UTAH","lead_sponsor":"University of Utah","biomarkers":" KRAS • BRAF • HRAS • RAS","pipe":" | ","alterations":" BRAF mutation","tags":["KRAS • BRAF • HRAS • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ulixertinib (BVD-523) • hydroxychloroquine"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 03/17/2020","start_date":" 03/17/2020","primary_txt":" Primary completion: 06/10/2022","primary_completion_date":" 06/10/2022","study_txt":" Completion: 08/18/2022","study_completion_date":" 08/18/2022","last_update_posted":"2024-03-20"},{"id":"b5bee8fd-2e25-44e8-bed2-34071fdc96d0","acronym":"","url":"https://clinicaltrials.gov/study/NCT02613650","created_at":"2021-01-18T12:41:52.148Z","updated_at":"2024-07-02T16:35:13.644Z","phase":"Phase 1","brief_title":"A Trial of mFOLFIRI With MEK162 in Patients With Advanced RAS (HRAS, NRAS, or KRAS) Positive Metastatic Colorectal Cancers","source_id_and_acronym":"NCT02613650","lead_sponsor":"University of Utah","biomarkers":" KRAS • HRAS","pipe":"","alterations":" ","tags":["KRAS • HRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mektovi (binimetinib) • irinotecan"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 08/19/2016","start_date":" 08/19/2016","primary_txt":" Primary completion: 12/21/2022","primary_completion_date":" 12/21/2022","study_txt":" Completion: 12/21/2022","study_completion_date":" 12/21/2022","last_update_posted":"2024-03-20"},{"id":"bd0915a0-fd20-4277-b54e-97bf1a6410c3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03452774","created_at":"2021-01-18T17:01:36.578Z","updated_at":"2024-07-02T16:35:14.464Z","phase":"","brief_title":"SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry","source_id_and_acronym":"NCT03452774","lead_sponsor":"Massive Bio, Inc.","biomarkers":" EGFR • HER-2 • PD-L1 • KRAS • BRAF • ER • ALK • TP53 • TMB • FLT3 • ABL1 • NRAS • BRCA1 • BRCA2 • FGFR2 • PTEN • ROS1 • IDH1 • NTRK1 • BCL2 • IDH2 • NTRK3 • NTRK2 • STK11 • NPM1 • HRAS • DNMT3A • ERBB3 • RB1 • CLDN18 • PDGFRA • NF1 • JAK2 • NRG1 • POLE • AKT1 • PD-1 • CCND1 • MCL1 • KDR • PBRM1 • BAP1 • VEGFA • BCL6 • PDGFRB • PTCH1 • FGFR4 • MSH6 • CDK4 • MSH2 • CTNNB1 • MAP2K2 • FBXW7 • WT1 • ATRX • BRCA • RAF1 • TSC2 • CHEK2 • PD-L2 • ERBB4 • JAK1 • FANCA • TSC1 • MDM4 • POLD1 • CDK6 • CEBPA • PARP1 • AURKA • JAK3 • RICTOR • CHEK1 • GATA6 • MSH3 • TGFBR2 • GNAS • MYCL • AKT2 • CCND2 • CCND3 • CSF1R • MAP3K1 • ERCC4 • HDAC1 • PRDM1 • ZNF217 • CDKN1A • GATA3 • PARP2 • PARP3 • SDHA • ACVR1B • ZNF703","pipe":" | ","alterations":" HER-2 mutation • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation","tags":["EGFR • HER-2 • PD-L1 • KRAS • BRAF • ER • ALK • TP53 • TMB • FLT3 • ABL1 • NRAS • BRCA1 • BRCA2 • FGFR2 • PTEN • ROS1 • IDH1 • NTRK1 • BCL2 • IDH2 • NTRK3 • NTRK2 • STK11 • NPM1 • HRAS • DNMT3A • ERBB3 • RB1 • CLDN18 • PDGFRA • NF1 • JAK2 • NRG1 • POLE • AKT1 • PD-1 • CCND1 • MCL1 • KDR • PBRM1 • BAP1 • VEGFA • BCL6 • PDGFRB • PTCH1 • FGFR4 • MSH6 • CDK4 • MSH2 • CTNNB1 • MAP2K2 • FBXW7 • WT1 • ATRX • BRCA • RAF1 • TSC2 • CHEK2 • PD-L2 • ERBB4 • JAK1 • FANCA • TSC1 • MDM4 • POLD1 • CDK6 • CEBPA • PARP1 • AURKA • JAK3 • RICTOR • CHEK1 • GATA6 • MSH3 • TGFBR2 • GNAS • MYCL • AKT2 • CCND2 • CCND3 • CSF1R • MAP3K1 • ERCC4 • HDAC1 • PRDM1 • ZNF217 • CDKN1A • GATA3 • PARP2 • PARP3 • SDHA • ACVR1B • ZNF703"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 mutation • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 50000","initiation":"Initiation: 01/01/2018","start_date":" 01/01/2018","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-03-15"},{"id":"a03225ff-24b0-4deb-bd39-a4f4a7489157","acronym":"","url":"https://clinicaltrials.gov/study/NCT05221320","created_at":"2022-02-05T18:29:02.167Z","updated_at":"2024-07-02T16:35:19.608Z","phase":"Phase 2","brief_title":"Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies","source_id_and_acronym":"NCT05221320","lead_sponsor":"BioMed Valley Discoveries, Inc","biomarkers":" KRAS • BRAF • MSI • HRAS • MAP2K1 • RAS • MAPK1 • MAPK3","pipe":" | ","alterations":" MSI-H/dMMR","tags":["KRAS • BRAF • MSI • HRAS • MAP2K1 • RAS • MAPK1 • MAPK3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ulixertinib (BVD-523) • hydroxychloroquine"],"overall_status":"Recruiting","enrollment":" Enrollment 215","initiation":"Initiation: 05/26/2022","start_date":" 05/26/2022","primary_txt":" Primary completion: 12/06/2024","primary_completion_date":" 12/06/2024","study_txt":" Completion: 03/19/2025","study_completion_date":" 03/19/2025","last_update_posted":"2024-02-13"},{"id":"5cdbdbf3-e8da-4789-91ba-999fa7089d8e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03454035","created_at":"2021-01-18T17:01:52.689Z","updated_at":"2024-07-02T16:35:22.023Z","phase":"Phase 1","brief_title":"Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors","source_id_and_acronym":"NCT03454035","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" KRAS • BRAF • NRAS • HRAS • NF1","pipe":" | ","alterations":" BRAF V600 • NF1 mutation • RAS mutation • KRAS G12 • NRAS Q61 • KRAS G13 • KRAS amplification • NRAS G12 • NRAS G13 • KRAS Q61 • HRAS Q61","tags":["KRAS • BRAF • NRAS • HRAS • NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600 • NF1 mutation • RAS mutation • KRAS G12 • NRAS Q61 • KRAS G13 • KRAS amplification • NRAS G12 • NRAS G13 • KRAS Q61 • HRAS Q61"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • ulixertinib (BVD-523)"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 01/30/2018","start_date":" 01/30/2018","primary_txt":" Primary completion: 07/15/2024","primary_completion_date":" 07/15/2024","study_txt":" Completion: 04/24/2026","study_completion_date":" 04/24/2026","last_update_posted":"2024-01-26"},{"id":"0f0b0890-fa2b-48fb-a929-8a1bc66f161c","acronym":"","url":"https://clinicaltrials.gov/study/NCT06104488","created_at":"2023-10-27T17:14:00.798Z","updated_at":"2024-07-02T16:35:31.349Z","phase":"Phase 1","brief_title":"A Study of Avutometinib for People With Solid Tumor Cancers","source_id_and_acronym":"NCT06104488","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" KRAS • NRAS • HRAS • NF1 • PTPN11","pipe":" | ","alterations":" NF1 mutation","tags":["KRAS • NRAS • HRAS • NF1 • PTPN11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avmapki (avutometinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 10/20/2023","start_date":" 10/20/2023","primary_txt":" Primary completion: 10/20/2029","primary_completion_date":" 10/20/2029","study_txt":" Completion: 10/20/2029","study_completion_date":" 10/20/2029","last_update_posted":"2023-10-27"},{"id":"4a7a80ea-21b3-4d81-8f03-943129f3e58b","acronym":"KURRENT-HN","url":"https://clinicaltrials.gov/study/NCT04997902","created_at":"2021-08-10T14:52:48.661Z","updated_at":"2024-07-02T16:35:31.801Z","phase":"Phase 1/2","brief_title":"Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)","source_id_and_acronym":"NCT04997902 - KURRENT-HN","lead_sponsor":"Kura Oncology, Inc.","biomarkers":" PIK3CA • HRAS","pipe":"","alterations":" ","tags":["PIK3CA • HRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Piqray (alpelisib) • Zarnestra (tipifarnib)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 12/07/2021","start_date":" 12/07/2021","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2023-10-25"},{"id":"c588db17-efc8-49b9-af67-a28b72dc4313","acronym":"","url":"https://clinicaltrials.gov/study/NCT06096974","created_at":"2023-10-24T15:13:42.150Z","updated_at":"2024-07-02T16:35:31.995Z","phase":"Phase 1","brief_title":"Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS","source_id_and_acronym":"NCT06096974","lead_sponsor":"Shanghai YingLi Pharmaceutical Co. Ltd.","biomarkers":" PD-L1 • KRAS • NRAS • HRAS","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • HRAS mutation","tags":["PD-L1 • KRAS • NRAS • HRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • HRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e YL-17231"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 10/01/2023","start_date":" 10/01/2023","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2023-10-24"},{"id":"6a7cc96b-1a8d-4c60-a5b9-6a9e7c5f86aa","acronym":"NBIBLI","url":"https://clinicaltrials.gov/study/NCT03748667","created_at":"2021-08-02T20:53:11.763Z","updated_at":"2024-07-02T16:35:36.493Z","phase":"","brief_title":"Accuracy for Predicting Deep Submucosal Invasion","source_id_and_acronym":"NCT03748667 - NBIBLI","lead_sponsor":"Althaia Xarxa Assistencial Universitària de Manresa","biomarkers":" EGFR • HER-2 • TP53 • PIK3CA • PTEN • HRAS • CDKN2A • ARID1A • CTNNB1 • FBXW7 • KMT2C • MUC16 • POLD1 • SETD2 • ARID2 • FAT4 • CSMD1 • DAPK1 • SYNE1 • PCLO • RYR3 • ZFHX4","pipe":"","alterations":" ","tags":["EGFR • HER-2 • TP53 • PIK3CA • PTEN • HRAS • CDKN2A • ARID1A • CTNNB1 • FBXW7 • KMT2C • MUC16 • POLD1 • SETD2 • ARID2 • FAT4 • CSMD1 • DAPK1 • SYNE1 • PCLO • RYR3 • ZFHX4"],"overall_status":"Completed","enrollment":" Enrollment 426","initiation":"Initiation: 12/01/2018","start_date":" 12/01/2018","primary_txt":" Primary completion: 09/28/2022","primary_completion_date":" 09/28/2022","study_txt":" Completion: 10/30/2022","study_completion_date":" 10/30/2022","last_update_posted":"2023-09-21"},{"id":"81882457-ba1a-48b0-8054-a1df3a396386","acronym":"TRAHD","url":"https://clinicaltrials.gov/study/NCT03714958","created_at":"2021-01-18T18:12:34.191Z","updated_at":"2025-02-25T15:43:15.903Z","phase":"Phase 1","brief_title":"Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer Mutant and TP53 Wild-type","source_id_and_acronym":"NCT03714958 - TRAHD","lead_sponsor":"Centre Leon Berard","biomarkers":" KRAS • TP53 • NRAS • HRAS","pipe":" | ","alterations":" TP53 mutation • BRAF mutation • TP53 wild-type • HRAS mutation","tags":["KRAS • TP53 • NRAS • HRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • BRAF mutation • TP53 wild-type • HRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • siremadlin (HDM201)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 12/20/2018","start_date":" 12/20/2018","primary_txt":" Primary completion: 09/12/2023","primary_completion_date":" 09/12/2023","study_txt":" Completion: 09/12/2023","study_completion_date":" 09/12/2023","last_update_posted":"2023-09-13"},{"id":"5cfcbe7d-4d03-4117-95be-9b8d7199f4ec","acronym":"","url":"https://clinicaltrials.gov/study/NCT04146298","created_at":"2021-01-18T20:14:11.889Z","updated_at":"2024-07-02T16:35:38.229Z","phase":"Phase 1/2","brief_title":"Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer","source_id_and_acronym":"NCT04146298","lead_sponsor":"Changhai Hospital","biomarkers":" KRAS • NRAS • HRAS","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • KRAS G12V • HRAS mutation • KRAS G12 • NRAS G12 • HLA-A*11 • NRAS G12V • KRAS expression","tags":["KRAS • NRAS • HRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • KRAS G12V • HRAS mutation • KRAS G12 • NRAS G12 • HLA-A*11 • NRAS G12V • KRAS expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 10/21/2021","start_date":" 10/21/2021","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2023-09-01"},{"id":"2f6706b3-4373-4123-bd41-4a6388aa2fbf","acronym":"","url":"https://clinicaltrials.gov/study/NCT04566393","created_at":"2021-01-18T21:48:48.647Z","updated_at":"2024-07-02T16:35:39.652Z","phase":"","brief_title":"Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies","source_id_and_acronym":"NCT04566393","lead_sponsor":"xCures","biomarkers":" BRAF • NRAS • HRAS • MAPK1","pipe":" | ","alterations":" BRAF mutation • ER mutation • HRAS mutation","tags":["BRAF • NRAS • HRAS • MAPK1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • ER mutation • HRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ulixertinib (BVD-523)"],"overall_status":"Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2023-08-21"}]